Full text is available at the source.
Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support
Jan 28, 2017The Cochrane database of systematic reviews
Comparing restrictive and liberal blood transfusion approaches for people with blood cancers undergoing intensive chemotherapy, radiotherapy, or stem cell support
AI simplified
Abstract
A restrictive red blood cell transfusion policy may reduce the number of transfusions per participant by an average of 3.58 units.
- Low-quality evidence suggests that a restrictive transfusion strategy has little or no impact on mortality within 100 days.
- The incidence of any bleeding or clinically significant bleeding appears to be similar between restrictive and liberal transfusion strategies.
- There is uncertainty regarding whether a restrictive strategy affects quality of life or the risk of serious infections.
- The length of hospital stay does not differ significantly between patients receiving restrictive versus liberal transfusions.
- Findings are primarily based on adults with acute leukaemia undergoing chemotherapy, and further studies are necessary, especially for children.
AI simplified
BACKGROUND: Many people diagnosed with haematological malignancies experience anaemia, and red blood cell (RBC) transfusion plays an essential supportive role in their management. Different strategies have been developed for RBC transfusions. A restrictive transfusion strategy seeks to maintain a lower haemoglobin level (usually between 70 g/L to 90 g/L) with a trigger for transfusion when the haemoglobin drops below 70 g/L), whereas a liberal transfusion strategy aims to maintain a higher haemoglobin (usually between 100 g/L to 120 g/L, with a threshold for transfusion when haemoglobin drops below 100 g/L). In people undergoing surgery or who have been admitted to intensive care a restrictive transfusion strategy has been shown to be safe and in some cases safer than a liberal transfusion strategy. However, it is not known whether it is safe in people with haematological malignancies.
OBJECTIVES: To determine the efficacy and safety of restrictive versus liberal RBC transfusion strategies for people diagnosed with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without a haematopoietic stem cell transplant (HSCT).
SEARCH METHODS: We searched for randomised controlled trials (RCTs) and non-randomised trials (NRS) in MEDLINE (from 1946), Embase (from 1974), CINAHL (from 1982), Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2016, Issue 6), and 10 other databases (including four trial registries) to 15 June 2016. We also searched grey literature and contacted experts in transfusion for additional trials. There was no restriction on language, date or publication status.
SELECTION CRITERIA: We included RCTs and prospective NRS that evaluated a restrictive compared with a liberal RBC transfusion strategy in children or adults with malignant haematological disorders or undergoing HSCT.
DATA COLLECTION AND ANALYSIS: We used the standard methodological procedures expected by Cochrane.
MAIN RESULTS: We identified six studies eligible for inclusion in this review; five RCTs and one NRS. Three completed RCTs (156 participants), one completed NRS (84 participants), and two ongoing RCTs. We identified one additional RCT awaiting classification. The completed studies were conducted between 1997 and 2015 and had a mean follow-up from 31 days to 2 years. One study included children receiving a HSCT (six participants), the other three studies only included adults: 218 participants with acute leukaemia receiving chemotherapy, and 16 with a haematological malignancy receiving a HSCT. The restrictive strategies varied from 70 g/L to 90 g/L. The liberal strategies also varied from 80 g/L to 120 g/L.Based on the GRADE rating methodology the overall quality of the included studies was very low to low across different outcomes. None of the included studies were free from bias for all 'Risk of bias' domains. One of the three RCTs was discontinued early for safety concerns after recruiting only six children, all three participants in the liberal group developed veno-occlusive disease (VOD). Evidence from RCTsA restrictive RBC transfusion policy may make little or no difference to: the number of participants who died within 100 days (two trials, 95 participants (RR: 0.25, 95% CI 0.02 to 2.69, low-quality evidence); the number of participants who experienced any bleeding (two studies, 149 participants; RR:0.93, 95% CI 0.73 to 1.18, low-quality evidence), or clinically significant bleeding (two studies, 149 participants, RR: 1.03, 95% CI 0.75 to 1.43, low-quality evidence); the number of participants who required RBC transfusions (three trials; 155 participants: RR: 0.97, 95% CI 0.90 to 1.05, low-quality evidence); or the length of hospital stay (restrictive median 35.5 days (interquartile range (IQR): 31.2 to 43.8); liberal 36 days (IQR: 29.2 to 44), low-quality evidence).We are uncertain whether the restrictive RBC transfusion strategy: decreases quality of life (one trial, 89 participants, fatigue score: restrictive median 4.8 (IQR 4 to 5.2); liberal median 4.5 (IQR 3.6 to 5) (very low-quality evidence); or reduces the risk of developing any serious infection (one study, 89 participants, RR: 1.23, 95% CI 0.74 to 2.04, very low-quality evidence).A restrictive RBC transfusion policy may reduce the number of RBC transfusions per participant (two trials; 95 participants; mean difference (MD) -3.58, 95% CI -5.66 to -1.49, low-quality evidence). Evidence from NRSWe are uncertain whether the restrictive RBC transfusion strategy: reduces the risk of death within 100 days (one study, 84 participants, restrictive 1 death; liberal 1 death; very low-quality evidence); decreases the risk of clinically significant bleeding (one study, 84 participants, restrictive 3; liberal 8; very low-quality evidence); or decreases the number of RBC transfusions (adjusted for age, sex and acute myeloid leukaemia type geometric mean 1.25; 95% CI 1.07 to 1.47 - data analysis performed by the study authors)No NRS were found that looked at: quality of life; number of participants with any bleeding; serious infection; or length of hospital stay.No studies were found that looked at: adverse transfusion reactions; arterial or venous thromboembolic events; length of intensive care admission; or readmission to hospital.
AUTHORS' CONCLUSIONS: Findings from this review were based on four studies and 240 participants.There is low-quality evidence that a restrictive RBC transfusion policy reduces the number of RBC transfusions per participant. There is low-quality evidence that a restrictive RBC transfusion policy has little or no effect on: mortality at 30 to 100 days, bleeding, or hospital stay. This evidence is mainly based on adults with acute leukaemia who are having chemotherapy. Although, the two ongoing studies (530 participants) are due to be completed by January 2018 and will provide additional information for adults with haematological malignancies, we will not be able to answer this review's primary outcome. If we assume a mortality rate of 3% within 100 days we would need 1492 participants to have a 80% chance of detecting, as significant at the 5% level, an increase in all-cause mortality from 3% to 6%. Further RCTs are required in children.
Related papers
May '24
Restrictive versus liberal red blood cell transfusion approaches for people with blood cancers undergoing intensive chemotherapy, radiotherapy, or stem cell support
cited by 5 papers
systematic review
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 21 papers
systematic review
Oct '25
Guiding red blood cell transfusions using transfusion limits and other methods
cited by 5 papers
systematic review
Dec '21
Blood level limits used to guide red blood cell transfusions
cited by 107 papers
systematic review
Oct '15
Comparing strict and relaxed red blood cell transfusion strategies for patients with bone marrow failure disorders
cited by 6 papers
systematic review
Apr '15
Red blood cell transfusion during hip fracture surgery
cited by 60 papers
systematic review
Mar '25
Managing red blood cell transfusions for people having heart surgery to fix birth defects
cited by 1 paper
systematic review
Oct '15
Different preventive platelet transfusion doses to reduce bleeding in people with blood disorders after chemotherapy or stem cell transplant
cited by 12 papers
systematic review
Nov '15
Comparing platelet count levels to guide preventive platelet transfusions for bleeding in blood disorder patients after chemotherapy or stem cell transplant
cited by 18 papers
systematic review
Aug '16
Other options and additions to preventive platelet transfusions for people with blood cancers receiving intense chemotherapy or stem cell transplants
cited by 15 papers
systematic review